Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00666328 · ClinicalTrials.gov registry record · Phase 3
Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE)
A Phase 3 study of Hypertension and Hemorrhage, sponsored by The Medicines Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 37
- Enrollment target
- 17
- Study locations
NCT00666328: Completed Phase 3 study of Hypertension and Hemorrhage, sponsored by The Medicines Company.
NCT00666328 is a Phase 3 study of Hypertension and Hemorrhage that has completed, run by The Medicines Company. The registered enrollment target is 37 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower). The trial reports 17 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00666328, a Phase 3 study of Hypertension and Hemorrhage, has completed, sponsored by The Medicines Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 37 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study was to determine the efficacy and safety of clevidipine for treating acute hypertension (high blood pressure, defined as systolic blood pressure \>160 mmHg) in patients with intracerebral hemorrhage (i.e., bleeding in the brain; stroke).
Primary Outcome
The median time, in minutes, was estimated with its two-tailed 95% confidence interval from the time of the initiation of clevidipine infusion until the first observed SBP was achieved in the target range of ≤160 mmHg to ≥140 mmHg within the first 30 minutes of clevidipine treatment. If patients did not reach the blood pressure target range within the first 30 minutes, their data was considered censored at 30 minutes. If another IV and/or oral antihypertensive agent indicated for hypertension wa
Conditions Studied
Interventions
- DRUG clevidipine
Study Locations (17)
North Carolina
- Duke University Medical Center - Durham
- Guilford Neurologic - Moses H Cone Health System - Greensboro
Ohio
- Cleveland Clinic Hospitals - Cleveland
- The Ohio State University - Columbus
Other
- Universitatsklinikum Erlangen - Erlangen
- Universitatsklinikum Heidelberg - Heidelberg
District of Columbia
- Washington Hospital Center - Washington D.C.
Hawaii
- The Queens Medical Center - Honolulu
Maryland
- The John Hopkins Hospital - Baltimore
Massachusetts
- Maine Medical Center - Portland
Michigan
- Henry Ford Hospital - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2008-06 |
| Est. Completion | 2010-04 |
| Phase | Phase 3 |
What the finished NCT00666328 record still lists
NCT00666328 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which clevidipine is the first listed.
NCT00666328 lists 17 locations in 14 states (North Carolina, Ohio, Other).
Frequently Asked Questions
What is clinical trial NCT00666328 about?
NCT00666328 is a clinical study titled "Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE)". The purpose of this study was to determine the efficacy and safety of clevidipine for treating acute hypertension (high blood pressure, defined as systolic blood pressure \>160 mmHg) in patients with intracerebral hemorrhage (i.e., bleeding in the brain; stroke).
What is the current status of trial NCT00666328?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 37 participants. The study started on 2008-06. Estimated completion is 2010-04.
What conditions does trial NCT00666328 study?
This clinical trial studies the following conditions: Hypertension, Hemorrhage.
What interventions are being tested in trial NCT00666328?
The interventions under investigation include: clevidipine (DRUG).
Who is sponsoring clinical trial NCT00666328?
This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00666328 being conducted?
This trial has 17 study locations across District of Columbia, Hawaii, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00666328's enrollment target sits among peer trials
37 396th of 470 higher than 74 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia